Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of a exenatide extended release ( Bydureon) on appetite and gastric emptying in Prader-Willi syndrome

Next Previous
X
Search
Trial Profile

The effects of a exenatide extended release ( Bydureon) on appetite and gastric emptying in Prader-Willi syndrome

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Acronyms ENGAGE PWS

    • Most Recent Events

    • 18 Jan 2019 According to Australian New Zealand Clinical Trials Registry, the anticipated date for last participant enrollment is 9/30/2019.
    • 18 Jan 2019 Planned End Date changed from 30 Jul 2017 to 28 Dec 2019.
    • 18 Jan 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top